RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM
Clin Cancer Res. 2016 22 (6): 1499-509

PMID: 26515496 · PMCID: PMC4794351 · DOI:10.1158/1078-0432.CCR-15-1125

MeSH Terms (22)

Animals B7-H1 Antigen Biomarkers Cell Line, Tumor Disease Models, Animal Disease Progression Female Gene Expression Profiling Humans Immunomodulation Immunophenotyping Lymphocytes, Tumor-Infiltrating Mice Mitogen-Activated Protein Kinases Mortality Phenotype Programmed Cell Death 1 Receptor Protein Kinase Inhibitors ras Proteins Signal Transduction Transcriptome Triple Negative Breast Neoplasms

Connections (3)

This publication is referenced by other Labnodes entities: